NRS 033
Alternative Names: Nalmefene prodrug - Nirsum Labs; NRS-033Latest Information Update: 23 Jan 2025
Price :
$50 *
At a glance
- Originator Nirsum Labs
- Class Drug withdrawal therapies; Small molecules
- Mechanism of Action Opioid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Opioid-related disorders
Most Recent Events
- 19 Dec 2024 Nirsum Labs plans a phase-II trial for Opioid use disorder and Alcohol use disorder
- 04 Dec 2024 Nirsum Labs completes phase-I clinical trials in Opioid-related disorders (In volunteers) in USA (Parenteral) (NCT05724797)
- 17 Apr 2023 Phase-I clinical trials in Opioid-related disorders (In volunteers) in USA (Parenteral) (NCT05724797),